Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual MeetingPRNewsWire • 03/08/22
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTSPRNewsWire • 03/01/22
Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022PRNewsWire • 02/15/22
Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing SchedulePRNewsWire • 02/02/22
Can Jazz (JAZZ) Climb 41% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 01/17/22
Strength Seen in Jazz (JAZZ): Can Its 9% Jump Turn into More Strength?Zacks Investment Research • 01/11/22
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical LeaderPRNewsWire • 01/10/22
Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic HypersomniaPRNewsWire • 01/05/22
Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/03/22
U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in AdultsPRNewsWire • 01/03/22